Medication adherence to inflammatory bowel disease medications in Aotearoa New Zealand and correlation with health outcomes: A nationwide database analysis
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16069 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Obreniokibo Ibifubara Amiesimaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Research Unit, Department of Medicine, Dunedin School of Medicine (DSM), University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Hospitalization, Colitis, Ulcerative, Databases, Factual, Crohn Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Medicine, DSM, University of Otago.
Abstract (Originalsprache)
Aims
Inflammatory bowel disease (IBD) management entails long‐term medication therapy. Worse disease outcomes and reduced quality of life might arise from poor medication adherence (MA). This study is the first to investigate patients with IBD's adherence across Aotearoa New Zealand and its relationship with disease outcomes.
Methods
Dispensing claims data (Pharmaceutical Collection) were used to calculate (3‐ and 5‐year) adherence, using daily polypharmacy possession ratio. Using hospitalization data (National Minimum Dataset), the relationship between adherence and the numbers of hospitalizations and corticosteroid dispensings was investigated.
Results
In total, 4654 patients (53% female; 55% Crohn's disease [CD], 45% ulcerative colitis [UC]; median age‐at‐first‐dispensing, 43 years) and 3148 patients (54% female; 55% CD, 44% UC; median age‐at‐first‐dispensing, 44 years) were in the 3‐ and 5‐year cohorts, respectively. The 3‐ and 5‐year cohorts had mean 4.6 and 4.2 IBD‐related hospitalizations and 6.9 and 9.2 corticosteroid dispensings, respectively. Average adherence estimates were 77.4% (95% confidence interval: 76.9–78.0%) and 74.9% (95% confidence interval: 74.1–75.6%; 3 and 5 years), while 54% and 51% of patients, respectively, had good adherence (MA ≥ 80%). There was no correlation between adherence and the numbers of hospitalizations (Pearson's R = −.0007; P = .65 and R = −.04; P = .02 [3 and 5 years]) and corticosteroid dispensings ( R = .08; P =
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Research Unit, Department of Medicine, Dunedin School of Medicine (DSM), University of Otago, Dunedin, New Zealand.
- Pharmaceutical Care Research Group, University of Basel, Basel, Switzerland.
- New Zealand Pharmacovigilance Centre, University of Otago, Dunedin, New Zealand.
- Gastroenterology Unit, Dunedin Hospital, Te Whatu Ora/Health New Zealand, Dunedin, New Zealand.
ORCID-Profile: Obreniokibo Ibifubara Amiesimaka
Förderung
- Department of Medicine, DSM, University of Otago
Zitieren
APA
Amiesimaka, O. I., Allemann, S. S., Braund, R., Schultz, M., & Aluzaite, K. (2024). Medication adherence to inflammatory bowel disease medications in Aotearoa New Zealand and correlation with health outcomes: A nationwide database analysis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16069
Vancouver
Amiesimaka OI, Allemann SS, Braund R, Schultz M, Aluzaite K. Medication adherence to inflammatory bowel disease medications in Aotearoa New Zealand and correlation with health outcomes: A nationwide database analysis. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16069
BibTeX
@article{Amiesimaka2024,
author = {Amiesimaka, Obreniokibo Ibifubara and Allemann, Samuel S and Braund, Rhiannon and Schultz, Michael and Aluzaite, Kristina},
title = {Medication adherence to inflammatory bowel disease medications in Aotearoa New Zealand and correlation with health outcomes: A nationwide database analysis},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16069}
}
EUVIMED